<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03131999</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00044389</org_study_id>
    <nct_id>NCT03131999</nct_id>
  </id_info>
  <brief_title>LAM Pilot Study With Imatinib Mesylate</brief_title>
  <acronym>LAMP-1</acronym>
  <official_title>LAM Pilot Study With Imatinib Mesylate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 clinical trial comparing imatinib mesylate to placebo for individuals with
      lymphangioleiomyomatosis (LAM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind, adjusted parallel design, randomized clinical trial comparing
      imatinib mesylate 400 mg daily or matching placebo on the primary outcome of log transformed
      serum VEGF-D level in patients with LAM.

      Sirolimus using patients will have co-administration of Imatinib mesylate or placebo for 28
      days prior to sirolimus discontinuation.

      The duration of 400 mg imatinib mesylate or placebo will be 56 days, a dose reduction is
      allowed for toxicity.

      The primary endpoint will be the change in the log transformed VEGF-D one month after
      monotherapy imatinib mesylate or placebo.

      Total trial duration is 2 months of drug administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum VEGF-D</measure>
    <time_frame>Before and 1 month after initiation of monotherapy imatinib mesylate or placebo</time_frame>
    <description>Change in the square root of the intrasubject plasma VEGF-D</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>Adverse event and Serious Adverse Event numbers using the CTCAE Version 4.03 definitions</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lung function</measure>
    <time_frame>2 months</time_frame>
    <description>FEV1 % predicted change</description>
  </other_outcome>
  <other_outcome>
    <measure>SGRQ</measure>
    <time_frame>2 months</time_frame>
    <description>Saint Georges Respiratory Questionnaire change</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lymphangioleiomyomatosis</condition>
  <arm_group>
    <arm_group_label>Imatinib Mesylate 400mg capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>56 days of Imatinib mesylate 400 mg oral daily with or without co-administration of an mTOR inhibitor for 28 days. A dose reduction to 200 mg daily is allowed for toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>56 days of Placebo with or without co-administration of an mTOR inhibitor for 28 days. A dose reduction is allowed for toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib Mesylate 400Mg Capsule</intervention_name>
    <description>Sirolimus or everolimus will be withdrawn after 28 days if used at baseline</description>
    <arm_group_label>Imatinib Mesylate 400mg capsule</arm_group_label>
    <other_name>Gleevec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Capsule</intervention_name>
    <description>Sirolimus or everolimus will be withdrawn after 28 days if used at baseline</description>
    <arm_group_label>Placebo Capsule</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Definite or Probable LAM

          -  FVC or Postbronchodilator FEV1 &lt;90% predicted

        Exclusion Criteria:

          -  Current or planned pregnancy or lactation

          -  Unwillingness to discontinue sirolimus

          -  Change in the dose or use of sirolimus within the past month

          -  Inability to perform spirometry

          -  Allergy or intolerance of albuterol and/or ipratropium

          -  Other serious illness that would impact the outcome of the study including cancer that
             has not received curative therapy, Grade III/IV cardiac problems as defined by the New
             York Heart Association Criteria. (i.e., congestive heart failure, myocardial
             infarction within 6 months of study), uncontrolled diabetes, chronic renal disease,
             chronic liver disease, or active uncontrolled infection

          -  Current lung transplant

          -  Known diagnosis of human immunodeficiency virus (HIV) infection

          -  Current cigarette smoking

          -  Required use of warfarin, ketoconazole, itraconazole, clarithromycin, or rifampin
             during the 2 months of the study.

          -  Unwillingness to avoid grapefruit juice or St. Johns Wort during the study.

          -  Planned surgery during the 2 months of the study.

          -  Patient with any significant history of non-compliance to medical regimens or with
             inability to grant reliable informed consent.

          -  Patient has received and other investigational agents within 28 days of first day of
             study drug dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Meinberg</last_name>
    <role>Study Director</role>
    <affiliation>Congressionally Directed Medical Research Programs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlie Strange, MD</last_name>
    <phone>843-792-3174</phone>
    <email>strangec@musc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kimberly Brown, MS</last_name>
    <phone>843-792-6474</phone>
    <email>brownkl@musc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanine D'Armiento, MD, PhD</last_name>
      <phone>212-305-3745</phone>
      <email>jmd12@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laura Fonseca</last_name>
      <phone>212-305-3745</phone>
      <email>lf2560@cumc.columbia.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlie Strange, MD</last_name>
      <phone>843-442-8061</phone>
      <email>strangec@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Brown, MS</last_name>
      <phone>843-792-6474</phone>
      <email>brownkl@musc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Charlie Strange</investigator_full_name>
    <investigator_title>Professor of Pulmonary and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>VEGF-D</keyword>
  <keyword>Imatinib mesylate</keyword>
  <keyword>Sirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphangioleiomyomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

